Ghetti G, Porta C, Povero M. Retifanlimab Vs Avelumab in Patients with Metastatic Merkel Cell Carcinoma: A Cost Utility Analysis in Italy. FE [Internet]. 2025 Mar. 13 [cited 2025 Jul. 22];26(1). Available from: https://provafe.seedstm.com/index.php/FE/article/view/1574